Arbutus Biopharma (ABUS) Cash from Restructuring (2018 - 2019)
Arbutus Biopharma's (ABUS) quarterly Cash from Restructuring came in at $917000.0 in Q4 2019, up 759.71% quarter-over-quarter from -$139000.0 in Q1 2019.
Arbutus Biopharma (ABUS) Cash from Restructuring (2018 - 2019) Analysis & Trends
Arbutus Biopharma has disclosed Cash from Restructuring across 2 years of filings, most recently posting $917000.0 for Q4 2019.
- Cash from Restructuring for Q4 2019 came in at $917000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2019 was $778000.0 (down 28.62% YoY), and the FY2018 annual result was $396000.0, changed N/A from the prior year.
- Cash from Restructuring came in at $917000.0 for Q4 2019 at Arbutus Biopharma, up from -$139000.0 in the prior quarter.
- In the past five years, Cash from Restructuring ranged from a high of $1.0 million in Q1 2018 to a low of -$139000.0 in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Arbutus Biopharma | 882.62 Mn | 882.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 917,000.00 |
| Mar 31, 2019 | -139,000.00 |
| Jun 30, 2018 | 61,000.00 |
| Mar 31, 2018 | 1.03 Mn |